Cenicriviroc, a dual CCR2/CCR5 inhibitor, as novel therapeutic strategy for liver fibrosis Jan. 8, 2014
Researchers from Curis present preliminary results of a first-in-human trial of CUDC-907 Jan. 7, 2014
Cornerstone Pharmaceuticals presents phase I results for CPI-613 in hematological malignancies Jan. 7, 2014
Incyte presents interim phase II results for INCB-039110 in patients with primary myelofibrosis Jan. 3, 2014
RSS